Cytochrome P450-Mediated Bioactivation of the Epidermal Growth Factor Receptor Inhibitor Erlotinib to a Reactive Electrophile

The epidermal growth factor receptor tyrosine kinase inhibitor erlotinib (ERL) is approved for treatment of non–small-cell lung cancer. Numerous reports of ERL-associated toxicities are consistent with immune-mediated toxicity, including drug-induced hepatitis, interstitial lung disease, Stevens-Joh...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Li, Xiaohai, Kamenecka, Theodore M., Cameron, Michael D.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Society for Pharmacology and Experimental Therapeutics 2010
Konular:
Articles
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3202369/
https://ncbi.nlm.nih.gov/pubmed/20382753
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1124/dmd.109.030361
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller